Monday, 27 July 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 27 July 2026
News

Pharma crowned PBAC winner

Posted 27 July 2026 AM

AstraZeneca was the leading performer in 2025, securing more PBAC recommendations than any other pharmaceutical company while Celltrion Healthcare, Novartis, and Roche finished in a tie for second place.

Not only did AstraZeneca score the greatest number of recommendations at 10 but it has already achieved a PBS listing for nine, including two new treatments – breast cancer drug Truqap and injectable asthma drug Tezspire.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (2)

Sales & Customer Relations (24)

Clinical & Medical, R&D (9)

Regulatory, Pharmacovigilance & QA (3)

Devices (1)

Other (15)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.